⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Accent Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Accent Therapeutics
↗Lexington, Massachusetts, United States
Accent Therapeutics is a privately held, clinical-stage oncology biotechnology company developing targeted small-molecule therapies against tumor vulnerabilities associated with genomic instability, chromosomal instability and replication stress. The company was founded around RNA-modifying protein biology and epitranscriptomics, but its current strategy encompasses broader intracellular enzyme targets and biomarker-driven precision oncology. ([accenttx.com](https://accenttx.com/news-events/accent-therapeutics-announces-company-launch-with-dollar40-million-series-a-financing-for-novel-precision-cancer-treatments-targeting-rna-modifying-proteins/?utm_source=openai))
Accent's current active lead program is ATX-295, an oral KIF18A inhibitor intended to selectively target chromosomally unstable and aneuploid tumors. The company also advanced ATX-559, an oral DHX9 inhibitor for molecularly defined cancers, but the associated Phase 1/2 study was terminated in February 2026 because of its adverse-event profile. Accent retains worldwide rights to the KIF18A program and has strategic relationships with AstraZeneca and Boehringer Ingelheim. ([accenttx.com](https://accenttx.com/approach-pipeline/?utm_source=openai))
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$178M disclosed/aggregated
Investors:Mirae Asset Capital Life Science, Mirae Asset Capital, Mirae Asset Venture Investment, The Column Group, Atlas Venture, EcoR1 Capital, GV, AbbVie Ventures, The Mark Foundation for Cancer Research, Droia Ventures, Bristol Myers Squibb, Johnson & Johnson Innovation – JJDC, Timefolio Capital, NS Investment, Undisclosed investors
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2 clinical development; ATX-295 is the current active lead program and is listed as Phase 1 on ClinicalTrials.gov. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06799065?utm_source=openai))
Modalities:Small molecule, Orally bioavailable small molecule inhibitors, Intracellular enzyme inhibitors, RNA-modifying protein inhibitors, Kinesin inhibitors, RNA/DNA helicase inhibitors
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AstraZeneca: 2020 discovery, development and commercialization collaboration focused on RNA-modifying protein therapeutics; Accent received $55M upfront and was eligible for up to approximately $1.1B in additional option fees and milestones, plus tiered royalties. ([accenttx.com](https://accenttx.com/news-events/accent-therapeutics-and-astrazeneca-to-discover-and-develop-novel-cancer-therapeutics-in-new-collaboration/?utm_source=openai)), Boehringer Ingelheim: 2025 asset purchase for an undisclosed preclinical small-molecule oncology program targeting tumors with high interferon-stimulated-gene expression; Boehringer assumed global research, development, manufacturing and commercialization responsibility. ([prnewswire.com](https://www.prnewswire.com/news-releases/boehringer-ingelheim-obtains-novel-preclinical-oncology-program-from-accent-therapeutics-302576299.html))
COMPETITION
Position:Emerging
Competitors:Volastra Therapeutics — developing KIF18A inhibitor programs in Phase 1 oncology studies. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/accent-halts-solid-tumor-trial-over-adverse-events-pivots-other-lead-cancer-program)), Iambic Therapeutics — developing a KIF18A inhibitor program for chromosomally unstable tumors. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/accent-halts-solid-tumor-trial-over-adverse-events-pivots-other-lead-cancer-program)), STORM Therapeutics — RNA-modifying enzyme and small-molecule oncology company. ([biopharmadive.com](https://www.biopharmadive.com/news/astrazeneca-accent-rna-cancer-drug/579189/?utm_source=openai)), Gotham Therapeutics — RNA-modifying protein drug-discovery company. ([biopharmadive.com](https://www.biopharmadive.com/news/astrazeneca-accent-rna-cancer-drug/579189/?utm_source=openai)), Arrakis Therapeutics — RNA-focused drug-discovery company using small-molecule approaches. ([biopharmadive.com](https://www.biopharmadive.com/news/astrazeneca-accent-rna-cancer-drug/579189/?utm_source=openai)), Skyhawk Therapeutics — RNA-focused small-molecule drug-discovery company. ([biopharmadive.com](https://www.biopharmadive.com/news/astrazeneca-accent-rna-cancer-drug/579189/?utm_source=openai)), Expansion Therapeutics — RNA-targeted small-molecule therapeutics company. ([biopharmadive.com](https://www.biopharmadive.com/news/astrazeneca-accent-rna-cancer-drug/579189/?utm_source=openai))
LEADERSHIP
Key Executives:
Shakti Narayan, PhD, JD - Chief Executive Officer
Serena Silver, PhD - Chief Scientific Officer
Jason Sager, MD - Chief Medical Officer
David Brower, MBA - Chief Business Officer and Head of Finance
Stuart J. Ince, PhD - Vice President, Program Leadership & Operations
Steve Mennen, PhD - Vice President, Pre-Clinical Development
Srinivas Parthasarathy, PhD - Vice President, Business Development & Strategy and Chief of Staff
Scientific Founders:Howard Y. Chang, MD, PhD — Stanford University scientist and co-founder. ([accenttx.com](https://accenttx.com/news-events/accent-therapeutics-announces-company-launch-with-dollar40-million-series-a-financing-for-novel-precision-cancer-treatments-targeting-rna-modifying-proteins/?utm_source=openai)), Chuan He, PhD — University of Chicago scientist and co-founder with expertise in RNA biology and epitranscriptomics. ([accenttx.com](https://accenttx.com/news-events/accent-therapeutics-announces-company-launch-with-dollar40-million-series-a-financing-for-novel-precision-cancer-treatments-targeting-rna-modifying-proteins/?utm_source=openai)), Robert A. Copeland, PhD — co-founder, former President and former Chief Scientific Officer; previously President of Research and CSO at Epizyme and a former GSK oncology research leader. ([accenttx.com](https://accenttx.com/news-events/accent-therapeutics-first-patient-dosed-phase-1-2-trial-atx-559-cso-transition/))
Board Members:Jason Rhodes — Chair; Atlas Venture. ([accenttx.com](https://accenttx.com/team/?utm_source=openai)), John Josey — The Column Group. ([accenttx.com](https://accenttx.com/team/?utm_source=openai)), David Paik — Mirae Asset Capital Life Science. ([accenttx.com](https://accenttx.com/team/?utm_source=openai)), Catherine Strader, PhD — Synergy Partners. ([accenttx.com](https://accenttx.com/team/?utm_source=openai)), Andres Tellez, PhD — Johnson & Johnson Innovation – JJDC. ([accenttx.com](https://accenttx.com/team/?utm_source=openai)), Shakti Narayan, PhD, JD — Chief Executive Officer and board member. ([accenttx.com](https://accenttx.com/team/?utm_source=openai))
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Accent Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.